Recent developments in clinical trials for the treatment of traumatic brain injury

Handbook of Clinical Neurology

Volumn 127, Issue , 2015, Pages 433-451

  Stein, Donald G ^a   Geddes, Rastafa I ^a   Sribnick, Eric A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant; Coagulopathy; Glutamate antagonist; Immunomodulator; Neuroprotectant; Pharmacology; Steroid

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN INJURIES; CLINICAL TRIAL (TOPIC); HUMAN; PROCEDURES;

BRAIN INJURIES; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 84924939833     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52892-6.00028-3     Document Type: Chapter

References (171)

1. Abdallah D.M., Nassar N.N., Abd-El-Salam R.M. Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus. Brain Res 2011, 1385:257-262.
2. Abdel Baki S.G., Schwab B., Haber M., et al. Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats. PLoS One 2010, 5:e12490.
3. Ahmed S.M., Weber J.T., Liang S., et al. NMDA receptor activation contributes to a portion of the decreased mitochondrial membrane potential and elevated intracellular free calcium in strain-injured neurons. J Neurotrauma 2002, 19:1619-1629.
4. Alderson P., Roberts I. Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 2000, CD000196.
5. Alnaeeli M., Wang L., Piknova B., et al. Erythropoietin in brain development and beyond. Anat Res Int 2012, 2012:953264.
6. Alonso A., Gonzalez C. Neuroprotective role of estrogens: relationship with insulin/IGF-1 signaling. Front Biosci (Elite Ed) 2012, 4:607-619.
7. Alves O.L., Doyle A.J., Clausen T., et al. Evaluation of topiramate neuroprotective effect in severe TBI using microdialysis. Ann N Y Acad Sci 2003, 993:25-34. discussion 48-53.
8. Amen D.G., Wu J.C., Taylor D., et al. Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. J Psychoactive Drugs 2011, 43:1-5.
9. Amiri-Kordestani L., Kamangar F., Zujewski J.A. Inflammatory breast cancer: yet another risk of the obesity epidemic?. J Natl Cancer Inst 2013, 105:1340-1342.
10. Arango M.F., Bainbridge D. Magnesium for acute traumatic brain injury. Cochrane Database Syst Rev 2008, CD005400.
11. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
12. Aruoma O.I., Halliwell B., Hoey B.M., et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6:593-597.
13. Avikainen V. Coagulation disorders in severely and critically injured patients. Ann Chir Gynaecol 1977, 66:269-277.
14. Bains M., Hall E.D. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta 2012, 1822:675-684.
15. Baker A.J., Rhind S.G., Morrison L.J., et al. Resuscitation with hypertonic saline-dextran reduces serum biomarker levels and correlates with outcome in severe traumatic brain injury patients. J Neurotrauma 2009, 26:1227-1240.
16. Beauchamp K., Mutlak H., Smith W.R., et al. Pharmacology of traumatic brain injury: where is the "golden bullet"?. Mol Med 2008, 14:731-740.
17. Belson K. N.F.L. agrees to settle concussion suit for $765 million. New York Times 2013, August 29, 2013.
18. Bentzer P., Mattiasson G., McIntosh T.K., et al. Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume. J Neurotrauma 2001, 18:275-285.
19. Blaylock R.L., Maroon J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy - a unifying hypothesis. Surg Neurol Int 2011, 2:107.
20. Bredberg A., Lavasani S. Targeting versus tinkering: explaining why the clinic is frustrated with molecular mapping of disease mechanisms. Med Hypotheses 2013, 81:553-556.
21. Brinton R.D., Thompson R.F., Foy M.R., et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008, 29:313-339.
22. Brown M.S., Eichorst D., Lala-Black B., et al. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 2009, 124:e681-e687.
23. Bulger E.M., May S., Brasel K.J., et al. Out-of-hospital hypertonic resuscitation following severe traumatic brain injury: a randomized controlled trial. JAMA 2010, 304:1455-1464.
24. Bulger E.M., May S., Kerby J.D., et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg 2011, 253:431-441.
25. Cartagena C.M., Phillips K.L., Williams G.L., et al. Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. Neuromolecular Med 2013, 15:504-514.
26. Cekic M., Cutler S.M., VanLandingham J.W., et al. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol Aging 2011, 32:864-874.
27. Centers for Disease Control What Is Traumatic Brain Injury, March 18, 2009 2009, [cited October 7, 2009], Available from. http://www.cdc.gov/ncipc/tbi/TBI.htm.
28. Chauhan N.B., Gatto R. Restoration of cognitive deficits after statin feeding in TBI. Restor Neurol Neurosci 2011, 29:23-34.
29. Chen G., Shi J., Ding Y., et al. Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats. Mediators Inflamm 2007, 2007:93431.
30. Chew E., Zafonte R.D. Pharmacological management of neurobehavioral disorders following traumatic brain injury - a state-of-the-art review. J Rehabil Res Dev 2009, 46:851-879.
31. Cole L.A. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol 2010, 8:102.
32. Cramer S.C., Fitzpatrick C., Warren M., et al. The beta-hCG+erythropoietin in acute stroke (BETAS) study: a 3-center, single-dose, open-label, noncontrolled, phase IIa safety trial. Stroke 2010, 41:927-931.
33. Dame C., Bartmann P., Wolber E., et al. Erythropoietin gene expression in different areas of the developing human central nervous system. Brain Res Dev Brain Res 2000, 125:69-74.
34. Dancause N., Nudo R.J. Shaping plasticity to enhance recovery after injury. Prog Brain Res 2011, 192:273-295.
35. Defense and Veterans Brain Injury Center DoD Numbers for Traumatic Brain Injury 2011 2011, [cited February 9, 2012], Available from. http://www.dvbic.org/TBI-Numbers.aspx.
36. Dodd S., Dean O., Copolov D.L., et al. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008, 8:1955-1962.
37. Edwards P., Arango M., Balica L., et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005, 365:1957-1959.
38. Erlich P. Experimental Researches on Specific Therapeutics, vol. 1907, The Harben Lectures 1908, HK Lewis, London.
39. Espinoza T.R., Wright D.W. The role of progesterone in traumatic brain injury. J Head Trauma Rehabil 2011, 26:497-499.
40. Etemadrezaie H., Baharvahdat H., Shariati Z., et al. The effect of fresh frozen plasma in severe closed head injury. Clin Neurol Neurosurg 2007, 109:166-171.
41. Faul M., Xu L., Wald M.M., et al. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002-2006 2010, Centers for Disease Control, Atlanta.
42. Feeser V.R., Loria R.M. Modulation of traumatic brain injury using progesterone and the role of glial cells on its neuroprotective actions. J Neuroimmunol 2011, 237:4-12.
43. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012, 13:225-239.
44. Gardner A., Iverson G.L., McCrory P. Chronic traumatic encephalopathy in sport: a systematic review. Br J Sports Med 2014, 48:84-90.
45. Gatson J.W., Liu M.M., Abdelfattah K., et al. Estrone is neuroprotective in rats after traumatic brain injury. J Neurotrauma 2012, 29:2209-2219.
46. Glantz L., Avramovich A., Trembovler V., et al. Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia. Exp Neurol 2005, 192:117-124.
47. Gogarten W., Van Aken H., Moskopp D., et al. A case of severe cerebral trauma in a patient under chronic treatment with cyclosporine A. J Neurosurg Anesthesiol 1998, 10:101-105.
48. Goldstein L.E., Fisher A.M., Tagge C.A., et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med 2012, 4:134ra60.
49. Gomes J.A., Stevens R.D., Lewin J.J., et al. Glucocorticoid therapy in neurologic critical care. Crit Care Med 2005, 33:1214-1224.
50. Grande P.O., Moller A.D., Nordstrom C.H., et al. Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements. Acta Anaesthesiol Scand 2000, 44:886-894.
51. Grenander A., Bredbacka S., Rydvall A., et al. Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol 2001, 13:49-56.
52. Guan J. Insulin-like growth factor-1 (IGF-1) derived neuropeptides, a novel strategy for the development of pharmaceuticals for managing ischemic brain injury. CNS Neurosci Ther 2011, 17:250-255.
53. Guerriero C., Cairns J., Perel P., et al. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011, 6:e18987.
54. Hall E.D. Antioxidant therapies for acute spinal cord injury. Neurotherapeutics 2011, 8:152-167.
55. Hang C.H., Shi J.X., Li J.S., et al. Expressions of intestinal NF-kappaB, TNF-alpha, and IL-6 following traumatic brain injury in rats. J Surg Res 2005, 123:188-193.
56. Hang C.H., Shi J.X., Sun B.W., et al. Apoptosis and functional changes of dipeptide transporter (PepT1) in the rat small intestine after traumatic brain injury. J Surg Res 2007, 137:53-60.
57. Hatton J., Rosbolt B., Empey P., et al. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008, 109:699-707.
58. Helmy A., De Simoni M.G., Guilfoyle M.R., et al. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol 2011, 95:352-372.
59. Ho A.M., Karmakar M.K., Dion P.W. Are we giving enough coagulation factors during major trauma resuscitation?. Am J Surg 2005, 190:479-484.
60. Hoots W.K. Non-overt disseminated intravascular coagulation: definition and pathophysiological implications. Blood Rev 2002, 16(Suppl 1):S3-S9.
61. Hukkelhoven C.W., Steyerberg E.W., Farace E., et al. Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials. J Neurosurg 2002, 97:549-557.
62. Ippolito C.J. Battlefield TBI: blast and aftermath. Psychiatric Times 2007, (8). http://www.searchmedica.com/resource.html?rurl=http://www.psychiatrictimes.com/display/article/10168/56916&q=Battlefield+TBI:+blast+and+aftermath.&c=ps&ss=psychTimesLink&p=Convera&fr=true&ds=0&srid=1.
63. Junpeng M., Huang S., Qin S. Progesterone for acute traumatic brain injury. Cochrane Database Syst Rev 2011, 1. CD008409.
64. Juul S.E., Stallings S.A., Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res 1999, 46:543-547.
65. Juul S.E., McPherson R.J., Bauer L.A., et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008, 122:383-391.
66. Keimowitz R.M., Annis B.L. Disseminated intravascular coagulation associated with massive brain injury. J Neurosurg 1973, 39:178-180.
67. Khan M., Im Y.B., Shunmugavel A., et al. Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J Neuroinflammation 2009, 6:32.
68. Kochanek P.M., Safar P.J. Therapeutic hypothermia for severe traumatic brain injury. JAMA 2003, 289:3007-3009.
69. Kochanek P.M., Clark R.S., Ruppel R.A., et al. Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: Lessons learned from the bedside. Pediatr Crit Care Med 2000, 1:4-19.
70. Kumura E., Sato M., Fukuda A., et al. Coagulation disorders following acute head injury. Acta Neurochir (Wien) 1987, 85:23-28.
71. Kunio N.R., Differding J.A., Watson K.M., et al. Thrombelastography-identified coagulopathy is associated with increased morbidity and mortality after traumatic brain injury. Am J Surg 2012, 203:584-588.
72. Kurki P.T. Safety aspects of the long term cyclosporin A therapy. Scand J Rheumatol Suppl 1992, 95:35-38.
73. Lesort M., Esclaire F., Yardin C., et al. NMDA induces apoptosis and necrosis in neuronal cultures. Increased APP immunoreactivity is linked to apoptotic cells. Neurosci Lett 1997, 221:213-216.
74. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
75. Lifshitz J., Sullivan P.G., Hovda D.A., et al. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion 2004, 4:705-713.
76. Loane D.J., Faden A.I. Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 2010, 31:596-604.
77. Lu D., Mahmood A., Goussev A., et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg 2004, 101:813-821.
78. Maas A.I., Murray G., Henney H., et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006, 5:38-45.
79. Marmarou A., Lu J., Butcher I., et al. IMPACT database of traumatic brain injury: design and description. J Neurotrauma 2007, 24:239-250.
80. Marshall L.F., Maas A.I., Marshall S.B., et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 1998, 89:519-525.
81. Marti H.H., Gassmann M., Wenger R.H., et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997, 51:416-418.
82. Martland H.S. Punch drunk. JAMA 1928, 91:1103-1107.
83. Masel B.E., DeWitt D.S. Traumatic brain injury: a disease process, not an event. J Neurotrauma 2010, 27:1529-1540.
84. Mazzeo A.T., Kunene N.K., Gilman C.B., et al. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. J Neurotrauma 2006, 23:962-975.
85. Mazzeo A.T., Brophy G.M., Gilman C.B., et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma 2009, 26:2195-2206.
86. Mbye L.H., Singh I.N., Carrico K.M., et al. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab 2009, 29:87-97.
87. McAllister T.W. Neurobiological consequences of traumatic brain injury. Dialogues Clin Neurosci 2011, 13:287-300.
88. Morrison L.J., Rizoli S.B., Schwartz B., et al. The Toronto prehospital hypertonic resuscitation-head injury and multi organ dysfunction trial (TOPHR HIT) - methods and data collection tools. Trials 2009, 10:105.
89. Morrison L.J., Baker A.J., Rhind S.G., et al. The Toronto prehospital hypertonic resuscitation-head injury and multiorgan dysfunction trial: feasibility study of a randomized controlled trial. J Crit Care 2011, 26:363-372.
90. Muizelaar J.P. Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol 1994, 366:389-400.
91. Muizelaar J.P., Marmarou A., Young H.F., et al. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J Neurosurg 1993, 78:375-382.
92. Muizelaar J.P., Kupiec J.W., Rapp L.A. PEG-SOD after head injury. J Neurosurg 1995, 83:942.
93. Mungenast A.E., Tsai L.H. Cognitive function in health and disease: the role of epigenetic mechanisms. Neurodegener Dis 2012, 10:191-194.
94. Nadeau S., Rivest S. Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor kappa B activity in the brain during endotoxemia. J Neurosci 2000, 20:3456-3468.
95. Narayan R.K., Michel M.E., Ansell B., et al. Clinical trials in head injury. J Neurotrauma 2002, 19:503-557.
96. National Center for Health Statistics Health, United States, 2010: with special feature on death and dying 2010, http://www.cdc.gov/nchs/data/hus/hus10.pdf.
97. Nayak C.D., Nayak D.M., Raja A., et al. Time-relative changes in the erythrocyte antioxidant enzyme activities and their relationship with Glasgow Coma Scale scores in severe head injury patients in the 21-day posttraumatic study period. Indian J Med Sci 2007, 61:381-389.
98. Neal M.D., Cushieri J., Rosengart M.R., et al. Preinjury statin use is associated with a higher risk of multiple organ failure after injury: a propensity score adjusted analysis. J Trauma 2009, 67:476-482. discussion 482-484.
99. Nishibe M., Barbay S., Guggenmos D., et al. Reorganization of motor cortex after controlled cortical impact in rats and implications for functional recovery. J Neurotrauma 2010, 27:2221-2232.
100. Nobelprize.org Paul Ehrlich - Biographical 2012, [cited June 12 2012], Available from. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1908/ehrlich-bio.html.
101. Norwood S.H., McAuley C.E., Berne J.D., et al. A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. J Am Coll Surg 2001, 192:161-167.
102. Norwood S.H., McAuley C.E., Berne J.D., et al. Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. Arch Surg 2002, 137:696-701. discussion, 701-702.
103. Offner H., Subramanian S., Parker S.M., et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol 2006, 176:6523-6531.
104. Ogihara T., Yoshinaga K., Kamahara Y., et al. Clinical efficacy of carvedilol in severe hypertension. J Cardiovasc Pharmacol 1991, 18(Suppl 4):S69-S72.
105. Olivecrona M., Rodling-Wahlstrom M., Naredi S., et al. Prostacyclin treatment and clinical outcome in severe traumatic brain injury patients managed with an ICP-targeted therapy: a prospective study. Brain Inj 2012, 26:67-75.
106. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969, 164:719-721.
107. Omalu B., Bailes J., Hamilton R.L., et al. Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. Neurosurgery 2011, 69:173-183. discussion 183.
108. Pahatouridis D., Alexiou G.A., Zigouris A., et al. Coagulopathy in moderate head injury. The role of early administration of low molecular weight heparin. Brain Inj 2010, 24:1189-1192.
109. Patel A.D., Gerzanich V., Geng Z., et al. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J Neuropathol Exp Neurol 2010, 69:1177-1190.
110. PhRMA 2013 Report: Medicines in development for neurological disorders 2013, http://www.phrma.org/meds-in-development/neurological-disorders.
111. Piilgaard H., Witgen B.M., Rasmussen P., et al. Cyclosporine A, FK506, and NIM811 ameliorate prolonged CBF reduction and impaired neurovascular coupling after cortical spreading depression. J Cereb Blood Flow Metab 2011, 31:1588-1598.
112. Ponce L.L., Navarro J.C., Ahmed O., et al. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology 2013, 20:31-38.
113. Pondaag W. Disseminated intravascular coagulation related to outcome in head injury. Acta Neurochir Suppl (Wien) 1979, 28:98-102.
114. Pratico D., Reiss P., Tang L.X., et al. Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury. J Neurochem 2002, 80:894-898.
115. Ramlackhansingh A.F., Brooks D.J., Greenwood R.J., et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol 2011, 70:374-383.
116. Reinstrup P., Nordstrom C.H. Prostacyclin infusion may prevent secondary damage in pericontusional brain tissue. Neurocrit Care 2011, 14:441-446.
117. Rhind S.G., Crnko N.T., Baker A.J., et al. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. J Neuroinflammation 2010, 7:5.
118. Ritzel R.M., Capozzi L.A., McCullough L.D. Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke. Horm Behav 2013, 63:238-253.
119. Roberts I. The CRASH-2 trial of an antifibrinolytic agent in traumatic haemorrhage: an international collaboration. Indian J Med Res 2007, 125:5-7.
120. Roberts I., Yates D., Sandercock P., et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004, 364:1321-1328.
121. Roberts I., Shakur H., Afolabi A., et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011, 377:1096-1101. 1101 e1-e2.
122. Roos Y.B. Tranexamic acid for traumatic brain injury. BMJ 2011, 343:d3958.
123. Rosenfeld J.V., Maas A.I., Bragge P., et al. Early management of severe traumatic brain injury. Lancet 2012, 380:1088-1098.
124. Rowson S., Duma S.M., Beckwith J.G., et al. Rotational head kinematics in football impacts: an injury risk function for concussion. Ann Biomed Eng 2012, 40:1-13.
125. Ruff R.M. Mild traumatic brain injury and neural recovery: rethinking the debate. NeuroRehabilitation 2011, 28:167-180.
126. Sanchez-Aguilar M., Tapia-Perez J.H., Sanchez-Rodriguez J.J., et al. Effect of rosuvastatin on cytokines after traumatic head injury. J Neurosurg 2013, 118:669-675.
127. Saulle M., Greenwald B.D. Chronic traumatic encephalopathy: a review. Rehabil Res Pract 2012, 2012:816069.
128. Schmidt O.I., Infanger M., Heyde C.E., et al. The role of neuroinflammation in traumatic brain injury. Eur J Trauma 2004, 30:135-149.
129. Schneider E.B., Efron D.T., MacKenzie E.J., et al. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma 2011, 71:815-819.
130. Schretlen D.J., Shapiro A.M. A quantitative review of the effects of traumatic brain injury on cognitive functioning. Int Rev Psychiatry 2003, 15:341-349.
131. Seeley W.W., Crawford R.K., Zhou J., et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
132. Shakur H., Roberts I., Bautista R., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010, 376:23-32.
133. Shibata M., Kumar S.R., Amar A., et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001, 103:1799-1805.
134. Shohami E., Beit-Yannai E., Horowitz M., et al. Oxidative stress in closed-head injury: brain antioxidant capacity as an indicator of functional outcome. J Cereb Blood Flow Metab 1997, 17:1007-1019.
135. Shohami E., Gati I., Beit-Yannai E., et al. Closed head injury in the rat induces whole body oxidative stress: overall reducing antioxidant profile. J Neurotrauma 1999, 16:365-376.
136. Simard J.M., Chen M., Tarasov K.V., et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006, 12:433-440.
137. Slemmer J.E., Shacka J.J., Sweeney M.I., et al. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem 2008, 15:404-414.
138. Stanley R.M., Bonsu B.K., Zhao W., et al. US estimates of hospitalized children with severe traumatic brain injury: implications for clinical trials. Pediatrics 2012, 129:e24-e30.
139. Stein D.G. Concepts of CNS plasticity and their implications for recovery after brain damage. Brain Injury Medicine: Principles and Practice 2012, 162-174. DemosMedical, New York. M.N. Zasler, D. Katz, R. Zafonte (Eds.).
140. Stein S.C., Smith D.H. Coagulopathy in traumatic brain injury. Neurocrit Care 2004, 1:479-488.
141. Stein S.C., Ganguly K., Belfield C.M., et al. Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma 2009, 26:1585-1592.
142. Stern R.A., Daneshvar D.H., Baugh C.M., et al. Clinical presentation of chronic traumatic encephalopathy. Neurology 2013, 81:1122-1129.
143. Sullivan P.G., Thompson M.B., Scheff S.W. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999, 160:226-234.
144. Talving P., Benfield R., Hadjizacharia P., et al. Coagulopathy in severe traumatic brain injury: a prospective study. J Trauma 2009, 66:55-61. discussion 61-62.
145. Talving P., Lustenberger T., Kobayashi L., et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010, 251:1-4.
146. Talving P., Lustenberger T., Inaba K., et al. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Arch Surg 2012, 147:251-255.
147. Tapia-Perez J., Sanchez-Aguilar M., Torres-Corzo J.G., et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008, 25:1011-1017.
148. Temkin N.R., Anderson G.D., Winn H.R., et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol 2007, 6:29-38.
149. Ungerstedt J.S., Grenander A., Bredbacka S., et al. Clotting onset time may be a predictor of outcome in human brain injury: a pilot study. J Neurosurg Anesthesiol 2003, 15:13-18.
150. Utagawa A., Truettner J.S., Dietrich W.D., et al. Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats. Exp Neurol 2008, 211:283-291.
151. Vagnozzi R., Signoretti S., Cristofori L., et al. Assessment of metabolic brain damage and recovery following mild traumatic brain injury: a multicentre, proton magnetic resonance spectroscopic study in concussed patients. Brain 2010, 133:3232-3242.
152. Velmahos G.C. Erythropoiesis and the mystery of an unexplained survival benefit. Ann Surg 2010, 251:5.
153. Vilalta A., Sahuquillo J., Rosell A., et al. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med 2008, 34:1384-1392.
154. Vink R., Nimmo A.J. Multifunctional drugs for head injury. Neurotherapeutics 2009, 6:28-42.
155. Vink R., Van Den Heuvel C. Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury. Expert Opin Investig Drugs 2004, 13:1263-1274.
156. Wafaisade A., Lefering R., Tjardes T., et al. Acute coagulopathy in isolated blunt traumatic brain injury. Neurocrit Care 2010, 12:211-219.
157. Walker C.T., Marky A.H., Petraglia A.L., et al. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res 2010, 1347:125-131.
158. Watson N.F., Barber J.K., Doherty M.J., et al. Does glucocorticoid administration prevent late seizures after head injury?. Epilepsia 2004, 45:690-694.
159. Wigginton J.G., Pepe P.E., Idris A.H. Rationale for routine and immediate administration of intravenous estrogen for all critically ill and injured patients. Crit Care Med 2010, 38:S620-S629.
160. Williams S., Raghupathi R., MacKinnon M.A., et al. In situ DNA fragmentation occurs in white matter up to 12 months after head injury in man. Acta Neuropathol 2001, 102:581-590.
161. Williams-Johnson J.A., McDonald A.H., Strachan G.G., et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2). A randomised, placebo-controlled trial. West Indian Med J 2010, 59:612-624.
162. Winter J.P., Plummer D., Bottini A., et al. Early fresh frozen plasma prophylaxis of abnormal coagulation parameters in the severely head-injured patient is not effective. Ann Emerg Med 1989, 18:553-555.
163. Wright D.W., Kellermann A.L., Hertzberg V.S., et al. ProTECT: A Randomized Clinical Trial of Progesterone for Acute Traumatic Brain Injury. Ann Emerg Med 2007, 49:391-402.
164. Xiao G., Wei J., Yan W., et al. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit Care 2008, 12:R61.
165. Xiong Y., Mahmood A., Chopp M. Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs 2009, 14:67-84.
166. Xiong Y., Mahmood A., Chopp M. Animal models of traumatic brain injury. Nat Rev Neurosci 2013, 14:128-142.
167. Ye Y., Perez-Polo J.R., Aguilar D., et al. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011, 106:925-952.
168. Young B., Runge J.W., Waxman K.S., et al. Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 1996, 276:538-543.
169. Yurkewicz L., Weaver J., Bullock M.R., et al. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 2005, 22:1428-1443.
170. Zhou M.L., Zhu L., Wang J., et al. The inflammation in the gut after experimental subarachnoid hemorrhage. J Surg Res 2007, 137:103-108.
171. Zlotnik A., Leibowitz A., Gurevich B., et al. Effect of estrogens on blood glutamate levels in relation to neurological outcome after TBI in male rats. Intensive Care Med 2012, 38:137-144.